Market news

Biohaven has seen its share price fall over several time frames, yet the stock still carries a valuation that ultimately has to rest on what its balance sheet is worth. With the stock changing hands around US$13.19, the live question is how that market value lines up against the company’s book value relative to the broader pharmaceuticals and biotech industry. Over the past 3 years, Biohaven shareholders have seen the stock decline about 49.3%, which puts the focus squarely on whether its...

Biohaven's (BHVN) stock performance is likely to remain focused on the outlook for its Kv7 program a

Pivotal study enrolment has been paused while Biohaven characterises a metabolite of opakalim and its safety in humans.

Biohaven stock plummeted Thursday after the company paused enrollment in a midstage study of its seizure treatment.

Biohaven Pharmaceutical (NYSE:BHVN) shares fell 1. 9% to $15.

Biohaven (BHVN) is facing a quieter stretch for major drug catalysts, and limited patient data and r

Biohaven (BHVN) has an average rating of overweight and mean price target of $23.33, according to an

On August 26, Biohaven (NYSE:BHVN) and SK Biopharmaceuticals announced a global licensing agreement covering opakalim, Biohaven’s lead epilepsy candidate, in a deal worth up to $795 million plus royalties. SK Biopharmaceuticals picks up exclusive worldwide rights to Biohaven’s Kv7 ion channel platform, while Biohaven walks away with $400 million in near-term cash. The timing lines […]

It signed a collaboration and licensing deal potentially worth $795 million.

Biohaven Ltd. maintains a Buy rating, driven by pivotal trial progress in protein degraders and a key licensing deal for its Kv7 platform. Click here for more.

SK and Biohaven hope opakalim will show differential benefit to Xenon’s rival focal epilepsy drug, azetukalner, in an upcoming pivotal readout.

Biohaven stock rallies 18% on a $795M out-licensing deal granting SK Biopharmaceuticals global rights to its Kv7 epilepsy platform, led by opakalim.

Biohaven Ltd. (NYSE:BHVN) shares gained 7% on Wednesday after the biotechnology company announced a strategic global licensing agreement with SK Biopharmaceuticals covering its Kv7 ion channel platform and epilepsy candidate opakalim.

Faced with a dwindling bank account after a series of research setbacks, Biohaven is letting go of its most advanced experimental drug in a deal one analyst viewed as a “surprising” transaction.

Biohaven (BHVN) jumps 13% on a $795M SK Biopharmaceuticals licensing deal for opakalim (BHV-7000).

Two prominent biopharmaceutical names, Biohaven Ltd. (NYSE:BHVN) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), are deepening their relationship across oncology. On July 20, Biohaven announced a clinical supply agreement with Regeneron to evaluate the combination of BHV-1530 and Regeneron’s cemiplimab (Libtayo) in patients with solid tumors. BHV-1530’s novel topoisomerase I (TopoIx) payload generates immunogenic cell death and […]

Detailed price information for Biohaven Ltd (BHVN-N) from The Globe and Mail including charting and trades.

Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today reported financial results for the second quarter ended June 30, 2026, and provided a review of recent accomplishments and anticipated upcoming developments.

Detailed price information for Biohaven Ltd (BHVN-N) from The Globe and Mail including charting and trades.